JAGX
Jaguar Health, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.71
−1.45%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.76
From 52W high−96.68%
Volume229362.00
Market cap$933738.63
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataSep 18, 2026
Open
$2.76
From 52W high
−96.68%
Volume
229362.00
Market cap
$933738.63
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
82.0
MomentumView details →
1D Return
−1.45%
YTD Return
−91.41%
SummaryUpdated Jun 1, 2026
Jaguar Health, Inc. (NASDAQ:JAGX) is a commercial-stage pharmaceutical company founded in 2013 and headquartered in San Francisco, California. The company went public in May 2015 and focuses on developing prescription medicines for gastrointestinal distress, particularly chronic and debilitating diarrhea conditions in both humans and animals. Jaguar Health operates through two primary segments: Human Health and Animal Health, with its lead commercial product being <b>Mytesi</b>, an FDA-approved treatment for HIV-related diarrhea.
Similar companies
Latest newsMore news →
Jaguar Health, Inc. agreed to issue 535,000 shares of common stock and a pre-funded warrant for 2,077,255 shares to Joshua Mailman in exchange for all of his shares of Napo Therapeutics S.p.A., closing on September 15, 2026.5d agoJaguar Health, Inc. issued 31,847 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 0.4 shares of Series Q Perpetual Preferred Stock.5d agoJaguar Health, Inc. issued 219,435 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 2.8 shares of Series Q Perpetual Preferred Stock.5d ago